FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4298194308> ?p ?o ?g. }

• W4298194308 endingPage "1460" @default.
• W4298194308 startingPage "1449" @default.
• W4298194308 abstract "BACKGROUND This Phase I trial was developed to determine the safety, biologic activity, and effects on hematopoietic recovery of PIXY321 following ifosfamide, carboplatin, and etoposide chemotherapy for children with recurrent or refractory solid tumors. METHODS Children (age < 22 years at diagnosis) received ifosfamide 1800 mg/m2/day x 5 days, carboplatin 400 mg/m2/day x 2 days, and etoposide 100 mg/m2/day x 5 days, followed by daily subcutaneous administration of PIXY321. Dose-limiting toxicity was defined as Grade IV toxicity related to PIXY321. Pharmacokinetic and endogenous cytokine production studies were conducted during Course 1, and peripheral blood (PB) progenitor cell and receptor expression studies were conducted during Course 1 when the white blood cell count recovered to ≥1000/mm3. RESULTS Twenty-four children received ifosfamide, carboplatin, and etoposide chemotherapy plus PIXY321, the latter at doses of 500 μg/m2/day (n = 3), 750 μg/m2/day (n = 6), 1000 μg/m2/day (n = 9), or 500 μg/m2/twice a day (n =6). PIXY321 was well tolerated, with only 1 dose-limiting toxicity (chills, occurring at a dose of 750 μg/m2/day). The maximum tolerated dose was not reached in this study. The median days to absolute neutrophil count recovery (≥1000/mm3) and platelet recovery (>100,000/mm3) during Course 1 following PIXY321 (1000 μg/m2/day) were 22 days (range, 5-33 days) and 20 days (range, 5-31 days), respectively. There was a 2500, 5000, 3000, and 390% increase in PB granulocyte-macrophage colony-forming units, erythrocyte blast-forming units, granulocyte erythrocyte macrophage and megakaryocyte colony-forming units, and CD34+ cells, respectively. CONCLUSIONS In summary, this pediatric Phase I trial demonstrated that PIXY321 was well tolerated by children and resulted in platelet recovery a median of 20 days after ICE chemotherapy and an increase in the number of PB progenitor cells above baseline. However, based on recent negative results with PIXY321 in randomized Phase II/III trials involving adult subjects, PIXY321 is not currently available for future trials involving children. Cancer 1998;83:1449-1460. © 1998 American Cancer Society." @default.
• W4298194308 created "2022-10-01" @default.
• W4298194308 creator A5001697191 @default.
• W4298194308 creator A5015043380 @default.
• W4298194308 creator A5019914745 @default.
• W4298194308 creator A5032957928 @default.
• W4298194308 creator A5034694248 @default.
• W4298194308 creator A5058268746 @default.
• W4298194308 creator A5067649002 @default.
• W4298194308 creator A5075246827 @default.
• W4298194308 creator A5090325707 @default.
• W4298194308 date "1998-10-01" @default.
• W4298194308 modified "2023-10-15" @default.
• W4298194308 title "A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors" @default.
• W4298194308 cites W1825974684 @default.
• W4298194308 cites W1860006956 @default.
• W4298194308 cites W1893281004 @default.
• W4298194308 cites W1933655774 @default.
• W4298194308 cites W1980560578 @default.
• W4298194308 cites W1988136679 @default.
• W4298194308 cites W2009011265 @default.
• W4298194308 cites W2035502158 @default.
• W4298194308 cites W2123472995 @default.
• W4298194308 cites W2247320038 @default.
• W4298194308 cites W2289512295 @default.
• W4298194308 cites W2425605911 @default.
• W4298194308 cites W36713696 @default.
• W4298194308 cites W4251458889 @default.
• W4298194308 cites W4252438878 @default.
• W4298194308 doi "https://doi.org/10.1002/(sici)1097-0142(19981001)83:7<1449::aid-cncr24>3.0.co;2-3" @default.
• W4298194308 hasPublicationYear "1998" @default.
• W4298194308 type Work @default.
• W4298194308 citedByCount "8" @default.
• W4298194308 countsByYear W42981943082012 @default.
• W4298194308 crossrefType "journal-article" @default.
• W4298194308 hasAuthorship W4298194308A5001697191 @default.
• W4298194308 hasAuthorship W4298194308A5015043380 @default.
• W4298194308 hasAuthorship W4298194308A5019914745 @default.
• W4298194308 hasAuthorship W4298194308A5032957928 @default.
• W4298194308 hasAuthorship W4298194308A5034694248 @default.
• W4298194308 hasAuthorship W4298194308A5058268746 @default.
• W4298194308 hasAuthorship W4298194308A5067649002 @default.
• W4298194308 hasAuthorship W4298194308A5075246827 @default.
• W4298194308 hasAuthorship W4298194308A5090325707 @default.
• W4298194308 hasBestOaLocation W42981943081 @default.
• W4298194308 hasConcept C112705442 @default.
• W4298194308 hasConcept C126322002 @default.
• W4298194308 hasConcept C141071460 @default.
• W4298194308 hasConcept C2776694085 @default.
• W4298194308 hasConcept C2777063308 @default.
• W4298194308 hasConcept C2777506904 @default.
• W4298194308 hasConcept C2778119113 @default.
• W4298194308 hasConcept C2778239845 @default.
• W4298194308 hasConcept C2781451048 @default.
• W4298194308 hasConcept C29730261 @default.
• W4298194308 hasConcept C71924100 @default.
• W4298194308 hasConcept C74133956 @default.
• W4298194308 hasConcept C90924648 @default.
• W4298194308 hasConcept C98274493 @default.
• W4298194308 hasConceptScore W4298194308C112705442 @default.
• W4298194308 hasConceptScore W4298194308C126322002 @default.
• W4298194308 hasConceptScore W4298194308C141071460 @default.
• W4298194308 hasConceptScore W4298194308C2776694085 @default.
• W4298194308 hasConceptScore W4298194308C2777063308 @default.
• W4298194308 hasConceptScore W4298194308C2777506904 @default.
• W4298194308 hasConceptScore W4298194308C2778119113 @default.
• W4298194308 hasConceptScore W4298194308C2778239845 @default.
• W4298194308 hasConceptScore W4298194308C2781451048 @default.
• W4298194308 hasConceptScore W4298194308C29730261 @default.
• W4298194308 hasConceptScore W4298194308C71924100 @default.
• W4298194308 hasConceptScore W4298194308C74133956 @default.
• W4298194308 hasConceptScore W4298194308C90924648 @default.
• W4298194308 hasConceptScore W4298194308C98274493 @default.
• W4298194308 hasIssue "7" @default.
• W4298194308 hasLocation W42981943081 @default.
• W4298194308 hasOpenAccess W4298194308 @default.
• W4298194308 hasPrimaryLocation W42981943081 @default.
• W4298194308 hasRelatedWork W1974421033 @default.
• W4298194308 hasRelatedWork W2028006583 @default.
• W4298194308 hasRelatedWork W2054697909 @default.
• W4298194308 hasRelatedWork W2116109317 @default.
• W4298194308 hasRelatedWork W2128723228 @default.
• W4298194308 hasRelatedWork W2147316169 @default.
• W4298194308 hasRelatedWork W239195424 @default.
• W4298194308 hasRelatedWork W2789166760 @default.
• W4298194308 hasRelatedWork W30231677 @default.
• W4298194308 hasRelatedWork W2133000900 @default.
• W4298194308 hasVolume "83" @default.
• W4298194308 isParatext "false" @default.
• W4298194308 isRetracted "false" @default.
• W4298194308 workType "article" @default.